Thus, since expensive production is a major barrier to the spread of CAR T cell therapies, it remains to be seen if the superior anti-tumor effect of well-differentiated CAR T cells in solid tumors could also be achieved using IL-2-based expansion, in spite of the tendency of IL-2-stimulated cells for early apoptosis. This evidence concerns the gene IL2 and neoplasm.